Long Acting Injection Prevents Women From HIV Infection
Researchers have discovered that injection of a long-lasting injection called cabotegravir, every 2 months is 89% more effective than Truvada pills in reducing the risk of HIV infection in women. Cabotegravir is being researched and developed by ViiV Healthcare, mostly owned by GlaxoSmithKline, Pfizer Inc and Shionogi Limited. The study was also sponsored by the United States National Institutes of Health (NIH), the Bill and Melinda Gates Foundation and ViiV. The study involved about 3200 women between 18 and 45 years across 7 countries in Sub-Saharan Africa which are Botswana, Kenya, Malawi, South Africa, Eswatini, Uganda and Zimbabwe.
